Momentum in Head and Neck Cancer Immunotherapy

On April 28, 2016, Jonathan D. Schoenfeld, M.D., M.Phil., M.P.H., radiation oncologist at the Brigham and Women’s Hospital/Dana-Farber Cancer Institute and assistant professor of radiation oncology at Harvard Medical School, discussed current immunotherapy treatment options for patients with head and neck cancer, and how close we are to making these treatments available to more patients.

Dr. Schoenfeld’s research focuses on the design and implementation of clinical, epidemiologic, and translational studies in head and neck and skin cancers. He is actively evaluating the immunologic effects of radiation therapy and exploring treatments combining radiation with novel immunotherapy drugs.

He received his medical degree from Harvard Medical School after completing a research fellowship at the University of Cambridge in the UK as a Gates Scholar. He performed his residency in radiation oncology in the Harvard Radiation Program and received a master of public health in clinical effectiveness from the Harvard T.H. Chan School of Public Health. Dr. Schoenfeld’s research focuses on the design and implementation of clinical, epidemiologic, and translational studies in head and neck and skin cancers. He is actively evaluating the immunologic effects of radiation therapy and exploring treatments combining radiation with novel immunotherapy drugs. His epidemiologic research has been featured in The New York Times, The PBS NewsHour, and The Washington Post.

This webinar is part of the Cancer Research Institute's webinar series, "Cancer Immunotherapy and You," which are offered free to the public and feature informative updates for patients and caregivers from leaders in cancer immunotherapy, followed by a Q&A. This series is presented by Genentech and LabAnswer and its employees, with generous support from Abbvie, Celldex Therapeutics, NewLink Genetics, and Regeneron. For more information on this webinar, or to register for upcoming webinars, please visit www.cancerresearch.org/webinars.